Articles by tag: pros-syndrome

EMA approved the first therapy for PROS: analysis of Vijoice

Despite the failure of the confirmatory study, EMA approved alpelisib for severe PROS syndrome. We analyze the mechanism, risks, and prospects of Vijoice.